Invega Hafyera Drug Interactions

Drugs Having Clinically Important Interactions with INVEGA HAFYERA: Because paliperidone palmitate is hydrolyzed to paliperidone, results from studies with oral paliperidone should be taken into consideration when assessing drug-drug interaction potential. In addition, consider the 6-month dosing interval and the half-life of INVEGA HAFYERA [see Pharmacology: Pharmacokinetics under Actions].
Table 10 presents clinically significant drug interactions with INVEGA HAFYERA. (See Table 10.)

Click on icon to see table/diagram/image

Drugs Having No Clinically Important Interactions with INVEGA HAFYERA: Based on pharmacokinetic studies with oral paliperidone, no dosage adjustment of INVEGA HAFYERA is required when administered concomitantly with valproate [see Pharmacology: Pharmacokinetics under Actions]. Additionally, no dosage adjustment is necessary for valproate when co-administered with INVEGA HAFYERA [see Pharmacology: Pharmacokinetics under Actions].
Pharmacokinetic interaction between lithium and INVEGA HAFYERA is unlikely.
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies indicate that CYP2D6 and CYP3A4 may be involved in paliperidone metabolism; however, there is no evidence in vivo that inhibitors of these enzymes significantly affect the metabolism of paliperidone. Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19; an interaction with inhibitors or inducers of these isozymes is unlikely [see Pharmacology: Pharmacokinetics under Actions].